Jeffrey A Bubis DO FACOI, FACP

Hematologic Oncology

Division Director, Florida Cancer Specialists and Research Institute

4689 US Highway 17 Ste 25Fleming Island, FL 32003
Phone+1 904-269-6526
Fax+1 904-269-6527

Dr. Bubis is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Bubis' full profile Already have an account?

Education & Training

Dartmouth-Hitchcock/Mary Hitchcock Memorial HospitalFellowship, Hematology and Medical Oncology, 2005
Philadelphia College of Osteopathic MedicineChief Residency, Internal Medicine, 2001 - 2002
Philadelphia College of Osteopathic MedicineResidency, Internal Medicine, 2000 - 2002
Philadelphia College of Osteopathic MedicineInternship, Transitional Year, 1999 - 2000
Philadelphia College of Osteopathic MedicineClass of 1999

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

FL State License 2005 - 2028
PA State License 2000 - 2002
AOA Board of Internal Medicine Hematology
AOA Board of Internal Medicine Oncology
National Board of Physicians and Surgeons Hematology
National Board of Physicians and Surgeons Internal Medicine
National Board of Physicians and Surgeons Oncology
Licensed in Florida (active) and Pennsylvania (inactive) Board Certified in Internal Medicine, Medical Oncology, and Hematology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 2 Certification MOSAIQ, Elekta - IMPAC Medical Systems, Inc., 2012, 2014-2017
CMS Meaningful Use Stage 1 Certification MOSAIQ, Elekta - IMPAC Medical Systems, Inc., 2012, 2014-2017
CMS Meaningful Use Stage 1 Certification MOSAIQ EMR, Elekta, 2012-2013

Publications & Presentations

PubMed

1 citations
Spontaneous Subdural Hematomas as Initial Presentation of Acquired Coagulopathy: A Case Report.
Natalia C Badillo-Velez, Yoan Rodriguez, Payam Nabizadeh-Eraghi, Jeffrey Bubis
Cureus. 2025-02-01
22 citations
TITAN: phase III study of doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early-stage triple-negative breast cancer
Denise A. Yardley, Edward Arrowsmith, Brooke R. Daniel, Janice F. Eakle, Adam Brufsky
Breast Cancer Research and Treatment. 2017-05-15
258 citations
Randomized Phase III Trial of Amrubicin Versus Topotecan As Second-Line Treatment for Patients With Small-Cell Lung Cancer
Joachim von Pawel, Robert M. Jotte, David R. Spigel, Mary O'Brien, Mark A. Socinski
Journal of Clinical Oncology. 2014-11-10

Journal Articles

Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer
Pawel J, Jotte R, Spigel DR, O’Brien MER, Socinski MA, Mezger J, Steins M, Bosuee L, Bubis J, Nackaerts K, Trigo JM, Clinigan P, Schutte, Lorigan P, Reck M, Domine M, ..., JCO, 1/1/2014
Trimodality therapy for stage II-III carcinoma of the esophagus: A dose-ranging study of concurrent capecitabine, docetaxel, and thoracic radiotherapy
Wood MD, Zaki BI, Gordon SR, Sutton JE, Lisovsky M, Gui J, Bubis JA, Dragnev KH, Rigas JR, Journal of Thoracic Oncology, 1/1/2013
First-line use of cabazitaxel in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (mCRPC): A three-arm study in comparison with docetaxel
Oudard S, Sengelov L, Mainwaring PN, Thiery-Vuillemin A, Theodore,C, Kulukov E, Yachnin J, Kocak I, Kataja VV, Luukkaa M, Nosov A, Hjelm-Eriksson M, Bubis J, et al, J Clin Oncol, 1/1/2012

Books/Book Chapters

Multidisciplinary Treatment and Management of Cancer in the Elderly
Chapter: Chemotherapy in the Older Cancer Patient
Bubis JA, Gautier M, Cohen HJEditors: Muss HB, Johnson KA, Hunter CP.Marcel Dekker, Inc.2006

Abstracts/Posters

Features of patients (pts) with metastatic breast cancer (mBC) and a circulating tumor cell count (CTCc) of 0
Bubis JA, Marsland TA, Justice KM, Edwards D, San Antonio Breast Cancer Symposium, 1/1/2007
Aneusomy of chromosome (chrom) 17: an alternative mechanism of low level HER-2/neu gene amplification that correlates with immunohistochemical (IHC) 2+ protein expression
Kaufman PA, Schwartz GN, Bubis JA, Cates J, Wells WA, Moore CP, Connelly EM, Muss HB, Weaver DL, San Antonio Breast Cancer Symposium, 1/1/2004
Docetaxel and carboplatin followed by a dose-ranging study of oral capecitabine, weekly docetaxel, and concomitant external beam radiotherapy for the treatment of pati...
Bubis JA, Rigas JR, Dragnev KH, Sutton JE, Gordon SR, Zaki B, Cole BF, Williams I, American Society of Clinical Oncology Annual Meeting, 1/1/2004

Lectures